Previous 10 | Next 10 |
LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London Healthcare Conference in Lo...
AC Immune (NASDAQ: ACIU ): Q3 Non-GAAP EPS of CHF0.26; GAAP EPS of CHF0.25 beats by CHF0.30 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical...
Company Provides Key Updates on Tau Pipeline Candidates LAUSANNE, Switzerland, Nov. 06, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced hi...
LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it will host a key opinion leader (KOL) meeting focused on pathologi...
TrovaGene (NASDAQ: TROV ) +56% on positive response to treatment in phase 1b/2 trial of onvansertib in patients with KRAS-mutated metastatic colorectal cancer. More news on: TrovaGene, Inc., Biogen Inc., Stamps.com Inc., Stocks on the move, Read more ...
AC Immune SA (NASDAQ: ACIU ) will receive the first milestone payment of CHF30M from Eli Lilly (NYSE: LLY ) on or before October 7, 2019. More news on: AC Immune SA, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Read more ...
Lilly to pay CHF30 million development milestone Recognizes progress in ACI-3024 Small Molecule Tau Morphomer™ development LAUSANNE, Switzerland, Sept. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today...
Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer’s and neurodegenerative diseases The clinical milestone highlights the strength of AC Immune’s Tau pipeline, one of the broadest in the field Reflects the compelling ...
As the US Department of Health and Human Services notes, Alzheimer’s disease (AD) is a degenerative brain disorder that results in cognitive decline and basic thinking skills which slowly gets worse over time. According to a 2019 Alzheimer’s disease facts and figures re...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...